4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

Company Overview

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments. The company has also evaluated gene therapy candidates in other disease areas, including rare disorders.

Founded in 2013 and headquartered in Emeryville, California, 4D Molecular Therapeutics conducts research and clinical development activities through collaborations and studies involving patients in the United States and other international markets. David Kirn, M.D., is the company’s co-founder and chief executive officer. 4D Molecular Therapeutics went public on the Nasdaq Stock Market in 2020, and its therapies remain investigational and subject to clinical and regulatory review.

Key Stats

• Today's Range: $11.74 to $12.88
• 50-Day Range: $10.80 to $15.88
• 52-Week Range: $6.96 to $16.93
• Volume: 683,488 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $657.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.22
• Consensus Rating: Moderate Buy

4D Molecular Therapeutics Stock Analysis - MarketRank™

4D Molecular Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 568th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

4D Molecular Therapeutics has a consensus price target of $30.22, representing about 154.0% upside from its current price of $11.90.

Amount of Analyst Coverage

4D Molecular Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 4D Molecular Therapeutics are expected to grow in the coming year, from ($4.14) to ($4.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 4D Molecular Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4D Molecular Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

4D Molecular Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.66% of the float of 4D Molecular Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

4D Molecular Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.

Change versus previous month

Short interest in 4D Molecular Therapeutics has recently increased by 2.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4D Molecular Therapeutics does not currently pay a dividend.

Dividend Growth

4D Molecular Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.60

News Sentiment

4D Molecular Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,780,316.00 in company stock.

Percentage Held by Insiders

7.90% of the stock of 4D Molecular Therapeutics is held by insiders.

Percentage Held by Institutions

99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FDMT
• CIK: 1650648
• Web: www.4dmoleculartherapeutics.com
• Phone: 510-505-2680
• Fax: N/A
• Employees: 196
• Year Founded: 2013

Price Target and Rating

• Average Price Target for 4D Molecular Therapeutics: $30.22
• High Price Target: $37.00
• Low Price Target: $20.00
• Potential Upside/Downside: +154.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.11 million
• Net Margins: -194.74%
• Pretax Margin: -194.74%
• Return on Equity: -41.33%
• Return on Assets: -35.90%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 8.03
• Quick Ratio: 8.03

Sales & Book Value

• Annual Sales: $85.21 million
• Price / Sales: 7.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.85 per share
• Price / Book: 1.34

Miscellaneous

• Outstanding Shares: 55,240,000
• Free Float: 50,880,000
• Market Cap: $657.36 million
• Optionable: Optionable
• Beta: 2.75